STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.…
Nine Month Profit Rebound Change The Bull Case For STAAR Surgical Stock?
STAAR Surgical Company (NASDAQ: STAA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 921 employees.
The shares were at 24.22 USD on 20 November 2026, down 9.0% over 52 weeks. Its 52-week range is 15.59 USD to 35.87 USD: the price is 32.5% below the high and 55.4% above the low.
Its market capitalisation is 1.22B USD.
STAAR Surgical Company reports return on equity of -23.4%, an operating margin of 6.8% and revenue down 12.0% year over year.
It holds more cash than debt, a net cash position of 172.77M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 28.56 USD is 17.9% above the current price. The next earnings report is expected on 2 March 2027.